Statera BioPharma (STU:7CB) EPS (Basic): €-2.25 (TTM As of Sep. 2022)


What is Statera BioPharma EPS (Basic)?

Statera BioPharma STU:7CB 20 EPS (Basic) is €-2.25 as of Sep. 2022. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Statera BioPharma's basic earnings per share (Basic EPS) for the three months ended in Sep. 2022 was €-0.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2022 was €-2.25.

Statera BioPharma's EPS (Diluted) for the three months ended in Sep. 2022 was €-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was €-2.25.

Statera BioPharma's EPS without NRI for the three months ended in Sep. 2022 was €-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was -0.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Statera BioPharma  (STU:7CB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Statera BioPharma EPS (Basic) Related Terms

Statera BioPharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma EPS (Basic) Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
EPS (Basic)
-0.11 -0.39 -2.57

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.40 -1.93 -0.18 -0.07 -0.07

Statera BioPharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Statera BioPharma's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-90.138-0)/35.110
=-2.57

Statera BioPharma's Basic EPS for the quarter that ended in Sep. 2022 is calculated as

Basic EPS (Q: Sep. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.382-0)/50.234
=-0.07

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-2.25 mean?
Statera BioPharma (STU:7CB) has a EPS (Basic) of €-2.25 as of Sep. 2022. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's EPS (Basic) too high?
Statera BioPharma's current EPS (Basic) is €-2.25. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's EPS (Basic) compare to NRBO and PALI?
Statera BioPharma's EPS (Basic) of €-2.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current EPS (Basic) is €-2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current EPS (Basic) of €-2.25. The current EPS (Basic) is €-2.25. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current EPS (Basic) is €-2.25 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.